CA2665771A1 - Methode et trousse de depistage et de traitement immunogene par translocation de la crt et de l'erp57 - Google Patents

Methode et trousse de depistage et de traitement immunogene par translocation de la crt et de l'erp57 Download PDF

Info

Publication number
CA2665771A1
CA2665771A1 CA2665771A CA2665771A CA2665771A1 CA 2665771 A1 CA2665771 A1 CA 2665771A1 CA 2665771 A CA2665771 A CA 2665771A CA 2665771 A CA2665771 A CA 2665771A CA 2665771 A1 CA2665771 A1 CA 2665771A1
Authority
CA
Canada
Prior art keywords
protein
erp57
calreticulin
translocation
gadd34
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2665771A
Other languages
English (en)
Inventor
Michel S. Obeid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2665771A priority Critical patent/CA2665771A1/fr
Publication of CA2665771A1 publication Critical patent/CA2665771A1/fr
Priority to US12/882,183 priority patent/US20110060120A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2665771A 2006-09-08 2009-03-05 Methode et trousse de depistage et de traitement immunogene par translocation de la crt et de l'erp57 Abandoned CA2665771A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2665771A CA2665771A1 (fr) 2009-03-05 2009-03-05 Methode et trousse de depistage et de traitement immunogene par translocation de la crt et de l'erp57
US12/882,183 US20110060120A1 (en) 2006-09-08 2010-09-14 Immunogenic treatment of cancer by peptides inducing the plasma membrane exposure of erp57

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2665771A CA2665771A1 (fr) 2009-03-05 2009-03-05 Methode et trousse de depistage et de traitement immunogene par translocation de la crt et de l'erp57

Publications (1)

Publication Number Publication Date
CA2665771A1 true CA2665771A1 (fr) 2010-09-05

Family

ID=42729309

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2665771A Abandoned CA2665771A1 (fr) 2006-09-08 2009-03-05 Methode et trousse de depistage et de traitement immunogene par translocation de la crt et de l'erp57

Country Status (1)

Country Link
CA (1) CA2665771A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106188A (zh) * 2021-12-30 2022-03-01 深圳市人民医院 靶向二硫化物异构酶a3的纳米抗体及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106188A (zh) * 2021-12-30 2022-03-01 深圳市人民医院 靶向二硫化物异构酶a3的纳米抗体及其应用
CN114106188B (zh) * 2021-12-30 2022-07-19 深圳市人民医院 靶向二硫化物异构酶a3的纳米抗体及其应用

Similar Documents

Publication Publication Date Title
US8263344B2 (en) Compounds regulating calreticulin, KDEL receptor and/or Erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment
ES2423482T3 (es) Inhibidores de proteína fosfatasa 1, de GADD34 y del complejo de proteína fosfatasa 1/GADD34, y usos de los mismos combinados con etopósido o mitomicina C
Shepherd et al. Angiotensin II triggers peripheral macrophage-to-sensory neuron redox crosstalk to elicit pain
Peters et al. Endoplasmic reticulum calcium depletion impacts chaperone secretion, innate immunity, and phagocytic uptake of cells
Meister et al. Calcium channel blocker verapamil enhances reticulum stress and death induced by proteasome inhibition in myeloma cells
US10302644B2 (en) Compositions and methods for treating multiple myeloma
US20090005302A1 (en) Method, apparatus, and compound for effecting localized, non-systemic, immunogenic treatment of cancer
US20220331286A1 (en) Cannabis limits cancer stem cell growth in poorly differentiated cancers
WO2008032153A2 (fr) Procédé et nécessaire pour réaliser un criblage et un traitement immunogène à l'aide de la translocation de crt et/ou d'erp57
US20220193047A1 (en) Methods of enhancing radiotherapy using ferroptosis inducers as radiosensitizers
US20080214452A1 (en) Method for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt translocation
Campos‐Martorell et al. Brain proteomics identifies potential simvastatin targets in acute phase of stroke in a rat embolic model
Allouche‐Fitoussi et al. Signaling pathways involved in human sperm hyperactivated motility stimulated by Zn2+
Jiang et al. Dynamin‐Related Protein 1 Is Involved in Mitochondrial Damage, Defective Mitophagy, and NLRP3 Inflammasome Activation Induced by MSU Crystals
US20090004178A1 (en) Pharmaceutical compound for blocking the crt or erp57 translocation
US20090010952A1 (en) Pharmaceutical compound for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt or erp57 translocation
CA2665771A1 (fr) Methode et trousse de depistage et de traitement immunogene par translocation de la crt et de l'erp57
US20090004134A1 (en) Kit for treating a health condition by inducing translocation of an erp57 protein to a cellular membrane
US20090048159A1 (en) Kit for treating a health condition by inducing translocation of a calreticulin protein to a cellular membrane
US20090004678A1 (en) Method for screening fertility and new compounds or molecules, using crt or erp57 translocation
US20090004172A1 (en) Service for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using erp57 translocation
US20090004211A1 (en) Method for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using erp57 translocation
US20090005305A1 (en) Service for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt translocation
Qing et al. Targeting lysosomal HSP70 induces acid sphingomyelinase‐mediated disturbance of lipid metabolism and leads to cell death in T cell malignancies
AU2007353320B2 (en) Radiation protection and treatment for exposure to gamma-radiation

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20130305